Xencor (XNCR) Free Cash Flow (2013 - 2026)
Xencor (XNCR) posted quarterly Free Cash Flow of -$68.2 million for Q1 2026, down 286.31% year-over-year from $36.6 million in Q1 2025, and down 29.11% quarter-over-quarter from -$52.9 million in Q4 2025.
Xencor (XNCR) Free Cash Flow (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Free Cash Flow for 14 consecutive years, with -$68.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 286.31% year-over-year to -$68.2 million; the TTM figure through Mar 2026 stood at -$188.8 million (down 11.77% YoY), while the FY2025 annual figure was -$138.3 million, up 33.62% from the prior year.
- Free Cash Flow fell to -$68.2 million in Q1 2026 per XNCR's latest filing, from -$52.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $31.9 million in Q2 2022 and bottomed at -$70.4 million in Q2 2024.
- Historically, Free Cash Flow has averaged -$30.9 million across 5 years, with a median of -$34.4 million in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 367.36% — and 2023, when it tumbled 1211.03%.
- Xencor's Free Cash Flow stood at -$34.4 million in 2022, then jumped by 149.97% to $17.2 million in 2023, then sank by 399.62% to -$51.5 million in 2024, then fell by 2.62% to -$52.9 million in 2025, then decreased by 29.11% to -$68.2 million in 2026.
- Business Quant data shows XNCR's Free Cash Flow at -$68.2 million in Q1 2026, -$52.9 million in Q4 2025, and -$31.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -56.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.20 Mn |
| Jun 30, 2026 | -56.20 Mn |
| Mar 31, 2026 | -68.24 Mn |
| Mar 31, 2026 | -68.24 Mn |
| Dec 31, 2025 | -52.85 Mn |
| Dec 31, 2025 | -52.85 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Jun 30, 2025 | -36.75 Mn |
| Jun 30, 2025 | -36.75 Mn |
| Mar 31, 2025 | -17.66 Mn |
| Mar 31, 2025 | -17.66 Mn |
| Dec 31, 2024 | -51.50 Mn |
| Dec 31, 2024 | -51.50 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -70.38 Mn |
| Jun 30, 2024 | -70.38 Mn |
| Mar 31, 2024 | -56.99 Mn |
| Mar 31, 2024 | -56.99 Mn |